KaloCyte, Inc.
KaloCyte, Inc. is a pre-clinical stage biotech company focused on developing ErythroMer™, a dried, bio-inspired artificial red blood cell that is shelf-stable without refrigeration. This innovative solution aims to address the critical need for blood substitutes in emergency situations where stored red blood cells are unavailable, undesirable, or in short supply. Founded by a team of experts in physiology, bioengineering, and trauma care, KaloCyte is supported by significant federal grants and investor funding, positioning it to advance to first-in-human trials.
Industries
Nr. of Employees
small (1-50)
KaloCyte, Inc.
670 West Baltimore Street, HSRF III, 8th Floor, Baltimore, Maryland 21201
KaloCyte, Inc. is currently seeking investment
KaloCyte, Inc. is seeking a seed investment in the range of 5m-20m
Patents
Compositions and methods for removing bio-synthetic nano-particles from bodily fluids
2024-12-10 • US-12161765-B2
View Details
Compositions and methods for removing bio-synthetic nano-particles from bodily fluids
2024-12-10 • US-12161765-B2
View DetailsProducts
Dried, reconstitutable oxygen carrier (bio-inspired artificial red blood cell)
A freeze-dried powder formulation containing purified hemoglobin encapsulated in a soft lipid nanoparticle shell with a pH-responsive regulator to facilitate oxygen uptake in the lungs and release in hypoxic tissues; designed for ambient storage and rapid reconstitution for emergency transfusion.
Dried, reconstitutable oxygen carrier (bio-inspired artificial red blood cell)
A freeze-dried powder formulation containing purified hemoglobin encapsulated in a soft lipid nanoparticle shell with a pH-responsive regulator to facilitate oxygen uptake in the lungs and release in hypoxic tissues; designed for ambient storage and rapid reconstitution for emergency transfusion.
Expertise Areas
- Artificial oxygen carrier development
- Nanomedicine and lipid nanoparticle formulation
- Lyophilization and ambient-stable formulation
- Preclinical safety and efficacy testing
Key Technologies
- Lipid nanoparticle encapsulation
- Lyophilization / freeze-drying
- Hemoglobin purification and nano-encapsulation
- pH-responsive small-molecule modulation of protein function
Key People
Investors
Comcast RISE
$5,000 funded.
Announced on 2023-08-23.
NYBC Ventures
Announced on 2023-05-11.
New York Blood Center
Announced on 2022-07-20.
University System of Maryland Momentum Fund
$300,000 funded.
Announced on 2020-06-08.
Small Business Innovation Research
$373,000 funded.
Announced on 2020-05-05.
BioGenerator
Announced on 2019-01-01.
Comcast RISE
$5,000 funded.
Announced on 2023-08-23.
NYBC Ventures
Announced on 2023-05-11.
New York Blood Center
Announced on 2022-07-20.
University System of Maryland Momentum Fund
$300,000 funded.
Announced on 2020-06-08.
Small Business Innovation Research
$373,000 funded.
Announced on 2020-05-05.
BioGenerator
Announced on 2019-01-01.
News & Updates
A new candidate, ErythroMer, is still in preclinical testing but could be more durable and versatile than the real thing.
The research park’s location and resources make it invaluable for life science startups.
Elaine Haynes discusses KaloCyte’s groundbreaking bio-inspired artificial red blood cells.
KaloCyte is a partner in a $46 million project led by the University of Maryland School of Medicine to develop an artificial whole blood product.
nnals of Medicine
The Long Quest for Artificial Blood
One of the most valuable substances in the world has never been replicated. Are we close?
By Nicola Twilley
February 3, 2025
BALTIMORE, January 28, 2025 – KaloCyte, Inc., a pre-clinical biotech startup company developing a bio-inspired red blood cell substitute called ErythroMer™, announced today that it has been selected to join Blue Knight, a strategic collaboration between the Biomedical Advanced Research and Development Authority ('BARDA') and Johnson & Johnson’s global incubator network, JLABS, supporting early-stage innovation and incubation of science and technologies to improve health security and unlock new approaches to solving health issues.
KaloCyte, a University of Maryland BioPark affiliate, will be a virtual resident within JLABS, a premier life science incubator program. They will keep their laboratories and offices in downtown Baltimore where they collaborate closely with the University of Maryland School of Medicine’s Center for Blood Oxygen Transport & Hemostasis (CBOTH).
A new candidate, ErythroMer, is still in preclinical testing but could be more durable and versatile than the real thing.
The research park’s location and resources make it invaluable for life science startups.
Elaine Haynes discusses KaloCyte’s groundbreaking bio-inspired artificial red blood cells.
KaloCyte is a partner in a $46 million project led by the University of Maryland School of Medicine to develop an artificial whole blood product.
nnals of Medicine The Long Quest for Artificial Blood One of the most valuable substances in the world has never been replicated. Are we close? By Nicola Twilley February 3, 2025
BALTIMORE, January 28, 2025 – KaloCyte, Inc., a pre-clinical biotech startup company developing a bio-inspired red blood cell substitute called ErythroMer™, announced today that it has been selected to join Blue Knight, a strategic collaboration between the Biomedical Advanced Research and Development Authority ('BARDA') and Johnson & Johnson’s global incubator network, JLABS, supporting early-stage innovation and incubation of science and technologies to improve health security and unlock new approaches to solving health issues. KaloCyte, a University of Maryland BioPark affiliate, will be a virtual resident within JLABS, a premier life science incubator program. They will keep their laboratories and offices in downtown Baltimore where they collaborate closely with the University of Maryland School of Medicine’s Center for Blood Oxygen Transport & Hemostasis (CBOTH).